Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Rodino-Klapac Louise | President, R&D and Tech Ops | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 21,423 | $22.22 | $476,019.06 | 203,900Direct | Form 4 filed 8 Sep 2026, on sec.gov (opens in a new tab)Filed 8 Sep 2026 | |
| Estepan Ian Michael | Chief Operating Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 24,799 | $22.22 | $551,033.78 | 177,184Direct | Form 4 filed 8 Sep 2026, on sec.gov (opens in a new tab)Filed 8 Sep 2026 | |
| Wong Ryan Ho-Yan | Chief Financial Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 13,272 | $22.22 | $294,903.84 | 121,792Direct | Form 4 filed 8 Sep 2026, on sec.gov (opens in a new tab)Filed 8 Sep 2026 | |
| Rothfuss Cristin | EVP, General Counsel | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 22,025 | $22.22 | $489,395.50 | 115,519Direct | Form 4 filed 8 Sep 2026, on sec.gov (opens in a new tab)Filed 8 Sep 2026 | |
| SEVERINO MICHAEL | Director, Chief Executive Officer | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 756,104 | Not reported | No price reported | 756,104Direct | Form 4 filed 29 Jul 2026, on sec.gov (opens in a new tab)Filed 29 Jul 2026 | |
| Barry Richard | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 2,983,542Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Mayo Stephen | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 18,640Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Chambers Michael Andrew | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 27,535Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Wigzell Hans Lennart Rudolf | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 42,098Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Connelly Deirdre P | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 22,100Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Boor Kathryn Jean | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 25,138Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Nicaise Claude | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 48,407Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| BEHRENS M KATHLEEN | Director | Sarepta Therapeutics, Inc.SRPT | OtherA · Grant or award from the company | 16,875 | Not reported | No price reported | 214,357Direct | Form 4 filed 5 Jun 2026, on sec.gov (opens in a new tab)Filed 5 Jun 2026 | |
| Mayo Stephen | Director | Sarepta Therapeutics, Inc.SRPT | SellS · Open-market or private sale | 7,239 | $17.02 | $123,207.78 | 1,765Direct | Form 4 filed 13 Mar 2026, on sec.gov (opens in a new tab)Filed 13 Mar 2026 | |
| Rothfuss Cristin | EVP, General Counsel | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 974 | $17.03 | $16,587.22 | 137,544Direct | Form 4 filed 13 Mar 2026, on sec.gov (opens in a new tab)Filed 13 Mar 2026 | |
| Wong Ryan Ho-Yan | Chief Financial Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 256 | $17.03 | $4,359.68 | 135,064Direct | Form 4 filed 13 Mar 2026, on sec.gov (opens in a new tab)Filed 13 Mar 2026 | |
| Estepan Ian Michael | Chief Operating Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 1,097 | $17.03 | $18,681.91 | 201,983Direct | Form 4 filed 13 Mar 2026, on sec.gov (opens in a new tab)Filed 13 Mar 2026 | |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 948 | $17.03 | $16,144.44 | 225,323Direct | Form 4 filed 13 Mar 2026, on sec.gov (opens in a new tab)Filed 13 Mar 2026 | |
| Wong Ryan Ho-Yan | Chief Financial Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 113 | $16.95 | $1,915.35 | 135,320Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 | |
| Wong Ryan Ho-Yan | Chief Financial Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 162 | $16.95 | $2,745.90 | 135,433Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 | |
| Rothfuss Cristin | EVP, General Counsel | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 346 | $16.95 | $5,864.70 | 138,518Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 | |
| Rothfuss Cristin | EVP, General Counsel | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 484 | $16.95 | $8,203.80 | 138,864Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 | |
| Estepan Ian Michael | Chief Operating Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 583 | $16.95 | $9,881.85 | 203,080Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 | |
| Estepan Ian Michael | Chief Operating Officer | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 1,036 | $16.95 | $17,560.20 | 203,663Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 | |
| Rodino-Klapac Louise | President, R&D and Tech Ops | Sarepta Therapeutics, Inc.SRPT | OtherF · Shares withheld to pay tax or exercise price | 895 | $16.95 | $15,170.25 | 226,271Direct | Form 4 filed 11 Mar 2026, on sec.gov (opens in a new tab)Filed 11 Mar 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.